Novel and preclinical treatment strategies in pneumococcal meningitis

Meningitis

Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis

J Neuroinflammation.

Masouris I, Klein M, Dyckhoff S, Angele B, Pfister HW, Koedel U

doi: 10.1186/s12974-017-0989-0.

MeningitisViral Infections, Non-HIV

Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey

Lancet Infect Dis.

Ouldali N, Levy C, Varon E, Bonacorsi S, Béchet S, Cohen R, Angoulvant F, The French Pediatric Meningitis Network

doi: 10.1016/S1473-

Meningitis

Long-term neurological and cognitive outcome, and quality of life in adults after pneumococcal meningitis

Clin Microbiol Infect.

Kloek AT, Brouwer MC, Schmand B, Tanck MWT, van de Beek D

doi: 10.1016/j.cmi.2020.01.020.

HIV / AIDSMeningitis

Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals

HIV Med.

Balasko A, Keynan Y

doi: 10.1111/hiv.12676.

Meningitis

Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis

Open Forum Infect Dis.

Stadelman AM, Ellis J, Samuels THA, Mutengesa E, Dobbin J, Ssebambulidde K, Rutakingirwa MK, Tugume L, Boulware DR, Grint D, Cresswell FV

doi: 10.1093/ofid/ofaa257.

Meningitis

Elevated Matrix Metalloproteinase Concentrations Offer Novel Insight Into Their Role in Pediatric Tuberculous Meningitis

J Pediatric Infect Dis Soc.

Li YJ, Wilkinson KA, Wilkinson RJ, Figaji AA, Rohlwink UK

doi: 10.1093/

Meningitis

Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study

Lancet Infect Dis.

McGill F, Griffiths MJ, Geretti AM, Micheal BD, Beeching NJ, McKee D, Scarlett P, Hart IJ, Mutton KJ, Jung A, Adan G, Gummery A, Wan Sulaiman WA, Ennis K, Martin AP, Haycox A, Miller A, Solomon T; UK Meningitis Study Investigators

doi: 10.1016/S1473-3099

Bacterial Infections

Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach

Infect Control Hosp Epidemiol.

Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, Mehler PS, Jenkins TC

doi: 10.1017/ice.2017.10.

HIV / AIDS

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Lancet HIV.

Schürmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, Hüser A, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Matthews RP

doi: 10.1016/S2352-3018(19)30372-8.

Related content

Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis

Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey

Long-term neurological and cognitive outcome, and quality of life in adults after pneumococcal meningitis

Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals

Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis

Elevated Matrix Metalloproteinase Concentrations Offer Novel Insight Into Their Role in Pediatric Tuberculous Meningitis

Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study

Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial